Scientists explore GLUT1 protein as a diagnostic clue for rare lung tumors

NCT ID NCT03645915

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a protein called GLUT1 could help doctors better classify lung neuroendocrine tumors. Researchers analyzed tumor samples from 36 patients to see if GLUT1 staining patterns matched tumor type. The goal was to find a more reliable diagnostic tool than current methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If GLUT1 staining proves reliable, it could become a new diagnostic tool to help classify lung neuroendocrine tumors.
What could go wrong: This is a small, early study (36 samples) looking at a diagnostic marker, not a treatment. The findings need much larger studies to confirm if GLUT1 is truly useful in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease lung neoplasm lung neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG TUMOR

Contacts and locations

Locations

CHU Amiens-Picardie

Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.